Short answer
Vir Biotechnology, Inc. (VIR) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$96M
- +41.0% YoY · −220.2% QoQ
- EPS (diluted)
- −$0.59
- +50.0% YoY · −205.4% QoQ
Source: XBRL data from the Vir Biotechnology, Inc. (VIR) Q3 2026 10-Q on SEC EDGAR. USD.
Vir Biotechnology, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $(188) thousand vs $(428) thousand YoY, with nominal license and collaboration change
- Operating loss $(104.658) million vs $(173.443) million YoY, net loss $(96.252) million vs $(163.141) million
- Research and development expense $80.040 million vs $151.463 million, contract manufacturing $25.755 million vs $9.644 million
- Cash, cash equivalents and investments $901.3 million, restricted cash $8.8 million at September 30, 2026
- Operating cash outflow $115.141 million, financing inflow $242.533 million, including $162.2 million public offering proceeds
Risk Factors
- New regulatory risk: FDA Fast Track designation for VIR-5500 in October 2026 may be revoked or fail to accelerate approval
- Competitive risk: FDA approval of the first U.S. CHD therapy in May 2026 could alter standards of care and physician adoption
- Financial risk: Cash, equivalents and investments of approximately $901.3 million fund operations for at least 12 months
- Clinical risk: Oncology trials may require dose or schedule modifications under FDA’s Project Optimus initiative
- Manufacturing risk: Limited third-party synthetic siRNA suppliers could cause raw-material shortages or delivery delays
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vir Biotechnology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.